Dren Bio Announces $65 Million Series B Financing To Advance Its Lead Asset Into The Clinic And To Accelerate Development Of New Product Candidates From Its Targeted Myeloid Engager And Phagocytosis Platform
Jun 14, 2022•about 3 years ago
Amount Raised
$65 Million
Round Type
series b
Description
Dren Bio, Inc. (“Dren Bio” or the “Company”) today announced the completion of their $65 million Series B financing, pushing the Company’s total capital received to date over $156 million. Following the financing, Dren Bio is well-capitalized to reach multiple key inflection points across both its drug discovery programs over the coming years.
FundzWatch™ Score
68
Medium Activity
Buyer Intent Analysis
Get personalized insights on buying likelihood
Funding Insights
Based on industry dataTech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech